Trial Profile

A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ontunisertib (Primary)
Indications Crohn's disease
Focus Adverse reactions
Acronyms STENOVA
Sponsors AgomAb Therapeutics

Most Recent Events

17 Nov 2025 According to Agomab Therapeutics NV media release, company intends to present detailed STENOVA results at a future scientific conference.
17 Nov 2025 According to Agomab Therapeutics NV media release, The company plans to discuss the STENOVA results with regulatory authorities and prepare for a Phase 2b study.
17 Nov 2025 Topline results presented in the AgomAb Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com